stockrow
Monday 9 November 2026
Export SPRB’s income statement to Excel — free account
Spruce Biosciences, Inc.
SPRBSpruce Biosciences, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $4.9 million, down 51.3% from fiscal 2023.
- Revenue
- −75.9%
- EPS
- −90.9%
- Free cash flow
- −152.1%
- Total debt
- +427.2%
Quarter to June 2026, against a year earlier
46.55
3.84
+8.99%
Follow SPRB
Alert me
Spruce Biosciences, Inc. (SPRB) P/E ratio
Spruce Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| 4 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CMPX Compass Therapeutics, Inc. compare | n/m |
| SPRB Spruce Biosciences, Inc. | n/m |
| MOLN Molecular Partners AG Sponsored ADR compare | n/m |
| YARW Yarrow Bioscience, Inc compare | n/m |
| TARA Protara Therapeutics, Inc. compare | n/m |
| CHRS Coherus Oncology, Inc. compare | n/m |
| CUE Cue Biopharma, Inc. compare | n/m |
| PDSB PDS Biotechnology Corporation compare | n/m |
| MENS Jyong Biotech Ltd. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)